Bank of America Corp DE Has $11.88 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bank of America Corp DE cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,799 shares of the company’s stock after selling 28,855 shares during the period. Bank of America Corp DE owned 0.26% of Krystal Biotech worth $11,875,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Covestor Ltd lifted its position in Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the period. KBC Group NV lifted its position in Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares during the period. Blue Trust Inc. increased its stake in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after acquiring an additional 433 shares during the last quarter. US Bancorp DE increased its stake in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares during the last quarter. Finally, Certuity LLC bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $214,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on KRYS. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 6th. Citigroup lowered their price target on Krystal Biotech from $215.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, May 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Guggenheim lowered their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $211.13.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $125.29 on Friday. The business has a 50 day simple moving average of $162.61 and a 200 day simple moving average of $167.37. Krystal Biotech, Inc. has a 52-week low of $125.02 and a 52-week high of $219.34. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of 41.90 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. On average, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).